CIRB/COG AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462),a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥1 to <31 Years Old with First Relapse Read more
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Read more
A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax Read more
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations Read more
RANDOMIZED PHASE II TRIAL OF ANTI-LAG-3 AND ANTI-PD-1 BLOCKADE VS. SOC IN PATIENTS WITH RECURRENT GLIOBLASTOMA Read more
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy Read more
Tumor Treating Fields (TTFields) with maintenance temozolomide (TMZ) and pembrolizumab versus TTFields concomitant with maintenance TMZ and placebo in participants with newly diagnosed glioblastoma. Keynote D58 Read more
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Read more
A Retrospective and Prospective Protocol to Evaluate Demographic and Clinical Outcomes in Neuro-Oncology Patients Read more
